GENFIT's Leadership Enhancement
A biopharmaceutical company dedicated to addressing rare and severe liver diseases, GENFIT has made a significant leadership move by appointing Dr. Pejvack Motlagh as its new Chief Medical Officer. This strategic enhancement underscores GENFIT's commitment to innovation and exceptional patient care.
Dr. Pejvack Motlagh's Role
Assuming the role of CMO, Dr. Motlagh will be a pivotal member of the Executive Committee at GENFIT. His primary responsibilities will involve overseeing the strategic direction and execution of the company’s clinical development plans, as well as leading the teams responsible for Clinical Operations, Biometrics, and Pharmacovigilance.
Extensive Experience in Pharmaceutical Industry
With over two decades in the pharmaceutical and biotechnology fields, Dr. Motlagh brings a wealth of experience in drug development across various therapeutic areas. His comprehensive background positions him to significantly impact GENFIT's clinical strategies and development pipeline.
Notable Previous Contributions
Before joining GENFIT, Dr. Motlagh served as CMO at Egle Therapeutics, focusing on therapies that target regulatory T cells for oncology and autoimmune disorders. Additionally, he took on the role of CMO at Mablink Biosciences, which specializes in the development of next-generation antibody-drug conjugates (ADCs). His earlier roles in large pharmaceutical firms also contributed to advancing numerous compounds from early-phase clinical development to market.
Dr. Motlagh's Vision
In his first remarks as GENFIT’s Chief Medical Officer, Dr. Motlagh expressed excitement about joining the company at a critical time. "I am thrilled to join GENFIT at a pivotal moment, as Acute on-Chronic Liver Failure becomes an increasingly important focus among the liver disease community. The company’s commitment to innovation and patient-centric development aligns perfectly with my own values. I look forward to working with the team to drive forward our clinical programs and make a meaningful impact in areas of high unmet medical need," he stated.
CEO's Enthusiastic Welcome
CEO Pascal Prigent also welcomed Dr. Motlagh, praising his substantial expertise in clinical development. Prigent remarked, "We are delighted to welcome Pejvack to GENFIT. His rich experience and proven leadership in both large pharmaceutical and innovative biotech companies will be invaluable as we continue to advance our pipeline and deliver on our mission to bring transformative therapies to patients."
About GENFIT
GENFIT, a frontrunner in liver disease research, is committed to enhancing patient lives by focusing on rare, severe liver diseases that are often unmet medically. Over its two-decade history, GENFIT has established a rich scientific heritage in the sector.
Current Focus Areas
Currently, GENFIT directs efforts toward developing therapies for Acute on-Chronic Liver Failure (ACLF) and its related conditions, including acute decompensation and hepatic encephalopathy. This targeting involves therapeutic products designed with complementary mechanisms to address critical pathophysiological issues.
Innovations and Approvals
GENFIT’s research and development portfolio boasts several innovative therapeutic candidates across various stages, which ensures a steady flow of updates in the industry. A major milestone for the company was the accelerated approval of Iqirvo® (elafibranor) by international regulatory bodies for treating Primary Biliary Cholangitis (PBC).
Diagnostic Ventures
In addition to its therapeutic developments, GENFIT has established a diagnostic franchise. Notably, NIS2+® is utilized to detect Metabolic dysfunction-associated steatohepatitis (MASH), formerly identified as NASH.
Contact Information
GENFIT is headquartered in Lille, France, while maintaining offices in Paris, Zurich, and Cambridge, MA, USA. For inquiries, the company can be reached at:
GENFIT | Investors
Tel: +33 3 2016 4000 | investors@genfit.com
GENFIT | Media
Stephanie Boyer – Press Relations | Tel: +33 3 2016 4000 | stephanie.boyer@genfit.com
Frequently Asked Questions
Who is the new Chief Medical Officer of GENFIT?
Dr. Pejvack Motlagh has been appointed as the new Chief Medical Officer of GENFIT.
What is GENFIT's primary focus?
GENFIT focuses on developing therapies for rare and severe liver diseases, particularly Acute on-Chronic Liver Failure.
What previous experience does Dr. Motlagh have?
Dr. Motlagh has over 20 years of experience in the pharmaceutical industry, having served as CMO in previous companies and contributing to clinical development strategies.
What is Iqirvo®?
Iqirvo® (elafibranor) is a therapy developed by GENFIT, recently approved for the treatment of Primary Biliary Cholangitis (PBC).
How can I contact GENFIT?
GENFIT can be contacted via phone at +33 3 2016 4000 or through their email addresses for investors and media inquiries.
